Antiserum against arginine vasotocin (AVT) was produced by immunizing a goat and two rabbits with a conjugate of human immunoglobulin (IgG) and AVT. An antiserum, with a maximum binding of 91% at a final dilution of 1:100 was obtained from rabbit No. 2 after the 19th intradermal injections of the conjugate.
Nine neurohypophysial peptides have been identified in vertebrates. 1,2) All are nonapeptides with a disulfate bridge between the cysteinyl residues in position 1 and 6. AVT is present in fishes and non-mammalian tetrapods (amphibians, reptiles and birds), while the vasopressins (arginine vasopressin, AVP or lysine vasopressin, LVP) have been identified only in mammals.
More recently, AVT has also been found in fetal mammalian neurohypophysis3,4) and in the pineal5,6,7), subcommissural organ8), cerebrospinal fluid9) and systemic plasma10) of adult mammals. Thus, AVT has remained unchanged during the course of evolution and is found in representatives of all vertebrate classes.
Within the last 30 years, the measurement of circulating concentrations of many peptide and steroid hormones has been made possible by the development of the RIA system. In spite of its demand for scientific research, AVT antiserum has been successfully produced by only a limited number of foreign scientists, because of its poor immunogenicity. ROSENBLOOM et al.11) have successfully produced an excellent anti-LVP sera (R 70 and R 71) using bovine thyroglobulin as a carrier protein to enhance the antigenicity. FERNSTROM et al.12) and NOUWEN et al. 13 ) produced anti-AVT and anti-AVP sera using thyroglobulin and hemocyanin as a carrier protein, respectively.
Production of Vasotocin Antiserum
In the present experiment we aimed to produce an anti-AVT serum using human IgG as a carrier protein because it is available in a highly purified form.
Materials and Methods
Preparation of Antigen Five mg each of AVT (Sigma, Lot 111F-03041) and human IgG (Green Cross Co., SF 703KU) were dissolved in 5ml of 0.9% NaCl solution containing 0.1M sodium phosphate (pH 7.4).14) Then four portions of 20mg 1-cyclohexyl-3-(2-morpholinoethyl)-carbodiimde metho-p-toluenesulfonate (Morpho CDI, Sigma, Lot 59 C-0312) were added at lh intervals to the mixture in order to synthesize an immunogenic conjugate.15) The protein-peptide conjugate was dialyzed against 0.9% NaCI solution
The antigenic conjugate (1mg AVT/ml) was completely emulsified in an equal volume of Freund's complete adjuvant (Difco Lab.) with vortex agitation.16) One female Saanen goat (6 months), weighing 18kg, and two adult, white female Japanese rabbits, weighing 2 kg, were used for immunization. For the goat, 0.5ml of the prepared conjugate was injected intradermally at several sites in the neck-shoulder region. For the rabbits, 1ml of the prepared conjugate was injected intradermally at several sites in the neck-shoulder region. The injection, once every two weeks, was repeated 17 and 19 times for goat and rabbits, respectively.
Bleeding
Two to 5ml of blood was collected every two weeks (in the non-injection week) from the jugular vein and ear artery in the goat and rabbits, respectively. The Antibody titers were measured by determining the percentage of added I125-AVT (Specific activity, 17400mCi, New England Nuclear, USA) bound in serially diluted (Final dilution:1:100,1:1000,1:10,000,1:100,000)
antiserum.
The composition of incubation system and the procedure is described in the RIA section.
Iodination and purification
AVT was iodinated by the lactoperoxidase-glucose oxidase method using Enzymobead reagent (Bio-Rad Lab.) and a reaction time of 9 min. The iodinated AVT was purified by applying the reaction mixture to a DEAE Sephadex A-25 column followed by a Sephadex G-25 column. The detailed procedure for iodination and purification has been described elsewhere. Lot. 22023) were serially diluted. These AVT analogs instead of AVT were incubated with the mixture described in the section on RIA.
Results and Discussion
The rise in AVT antibody titer in a goat and two rabbits was measured by the ability of the antiserum to bind an added radioactive tracer. A rapid and progressive rise in titer was observed in rabbit No.2, while the remaining animals showed a slow rise throughout the immunization period, in which the goat exhibited the poorest
response. This appears to suggest that the rabbit is a better animal for the production of an antibody against AVT than the goat. However, this remains to be examined.
No serious infection was observed in all three animals, though the area where the AVT-human IgG conjugate was repeatedly injected showed mild inflamma- The titer is shown as a percentage of bound over total labeled AVT added in assay tube. A=1:100, B=1:1000, C=1:10,000, D=1:100,000 tion. Further, no signs of distress were observed during immunization, indicating that the animals used remained in fairly good condition. In rabbit No. 2 the percentage of added tracer bound in the presence of excess antibody reached 84.7% at one week after the 7th injection (Fig. 1) . The titer in this rabbit increased markedly with subsequent injections. We sacrificed this rabbit one week after the 19th injection, when 91% of the added radioactive tracer was bound by the antiserum in a final dilution of 1:100. This antiserum, which we named R 2-Kyushu, can be used at a final dilution of 1:100,000 (about 40% binding) for the AVT RIA.
An example of the standard curve for AVT RIA using R2-Kyushu antiserum is shown in Fig. 2 . A good dose-response line is seen between the concentration of AVT the cross-reactivity of R 2-Kyushu antiserum to naturally occurring neurohypophyseal peptides other than the above mentioned peptides has not yet been examined, this antiserum could be used to measure the samples from amphibians and reptiles since no significant cross-reaction with MT has occurred and no AVP has been detected in these species, or in birds. Further evaluation of the AVT RIA was demonstrated by 
